GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) Therapy
- Conditions
- Hepatitis B, Chronic
- Interventions
- First Posted Date
- 2022-03-11
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 174
- Registration Number
- NCT05276297
- Locations
- 🇬🇧
GSK Investigational Site, Leicester, United Kingdom
Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps
- Conditions
- Nasal Polyps
- Interventions
- Biological: Depemokimab (GSK3511294)Drug: Placebo
- First Posted Date
- 2022-03-10
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 276
- Registration Number
- NCT05274750
- Locations
- 🇬🇧
GSK Investigational Site, Wigan, United Kingdom
A Study to Evaluate Pharmacokinetic, Safety, Tolerability and Relative Bioavailability of Gepotidacin in Healthy Adult Male and Female Participants
- First Posted Date
- 2022-03-09
- Last Posted Date
- 2023-01-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 24
- Registration Number
- NCT05271799
- Locations
- 🇺🇸
GSK Investigational Site, Las Vegas, Nevada, United States
Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)
- Conditions
- Eosinophilic Granulomatosis With Polyangiitis
- Interventions
- Drug: Placebo matching depemokimab
- First Posted Date
- 2022-03-03
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 160
- Registration Number
- NCT05263934
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult Participants
- Conditions
- COVID-19SARS-CoV-2
- Interventions
- Biological: CV2CoV (2 µg)Biological: CV2CoV (8 µg)Biological: CV2CoV (20 µg)Biological: CV2CoV (4 µg)Biological: CV2CoV (12 µg)Biological: CV2CoV (16 µg)
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 99
- Registration Number
- NCT05260437
- Locations
- 🇺🇸
GSK Investigational Site, West Jordan, Utah, United States
🇺🇸Accel Research Sites, Lakeland, Florida, United States
🇺🇸MD Clinical - Velocity, Hallandale Beach, Florida, United States
An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)
- Conditions
- Asthma
- Interventions
- Biological: GSK3511294 (Depemokimab)
- First Posted Date
- 2022-02-17
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 641
- Registration Number
- NCT05243680
- Locations
- 🇬🇧
GSK Investigational Site, Nottingham, United Kingdom
A Study of Safety, Reactogenicity and Immune Response of the Repeat Vaccination Against RSV When Given to Female Participants of 18-49 Years of Age During Their Subsequent Uncomplicated Pregnancy
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Biological: RSV MAT
- First Posted Date
- 2022-02-08
- Last Posted Date
- 2022-04-07
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT05229068
- Locations
- 🇺🇸
GSK Investigational Site, Norfolk, Nebraska, United States
A Study on the Immune Response and Safety of a Vaccine Against Herpes Zoster in Adults Aged 50 Years and Older in India
- First Posted Date
- 2022-02-02
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 288
- Registration Number
- NCT05219253
- Locations
- 🇮🇳
GSK Investigational Site, Pune, India
Safety, Tolerability, Pharmacokinetics and Target Engagement of GSK3858279 in Healthy Caucasian, Chinese and Japanese Participants
- First Posted Date
- 2021-12-30
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 33
- Registration Number
- NCT05174013
- Locations
- 🇦🇺
GSK Investigational Site, Melbourne, Victoria, Australia
A Study to Evaluate the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine in Healthy Non-pregnant Females From 9 to 49 Years of Age
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Combination Product: RSV MAT vaccineCombination Product: dTpa vaccine
- First Posted Date
- 2021-12-27
- Last Posted Date
- 2023-04-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 9
- Registration Number
- NCT05169905
- Locations
- 🇺🇸
GSK Investigational Site, Beaumont, Texas, United States